Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia

References

• Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23. doi:10.1016/j.phrs.2015.07.010
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934. doi:10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008;8(6):853–864. doi:10.1586/14737140.8.6.853
   PubMed Web of Science ®Google Scholar
• Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schioth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20(11):839–861. doi:10.1038/s41573-021-00252-y
   PubMed Web of Science ®Google Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28. doi:10.1126/science.959840
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–880. doi:10.1126/science.1062538
   PubMed Web of Science ®Google Scholar
• Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49. doi:10.1186/s12943-018-0780-6
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–293. doi:10.1038/243290a0
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306(5940):239–242. doi:10.1038/306239a0
   PubMed Web of Science ®Google Scholar
• Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93–99. doi:10.1016/0092-8674(84)90077-1
   PubMed Web of Science ®Google Scholar
• Groffen J, Stephenson JR, Heisterkamp N, Bartram C, de Klein A, Grosveld G. The human c-abl oncogene in the Philadelphia translocation. J Cell Physiol Suppl. 1984;3:179–191. doi:10.1002/jcp.1041210421
   PubMedGoogle Scholar
• Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40(2 Suppl 2):4–10. doi:10.1053/shem.2003.50034
   PubMed Web of Science ®Google Scholar
• Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(Suppl 2):S107–21. doi:10.1007/s00277-015-2325-z
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824–830. doi:10.1126/science.2406902
   PubMed Web of Science ®Google Scholar
• Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87(17):6649–6653. doi:10.1073/pnas.87.17.6649
   PubMed Web of Science ®Google Scholar
• Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9(4):1069–1078. doi:10.1002/j.1460-2075.1990.tb08212.x
   PubMed Web of Science ®Google Scholar
• Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: an Update. Int J Mol Sci. 2019;20:24. doi:10.3390/ijms20246141
   Web of Science ®Google Scholar
• Soverini S, de Benedittis C, Mancini M, Martinelli G. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S120–8. doi:10.1016/j.clml.2015.02.035
   PubMed Web of Science ®Google Scholar
• Soverini S, Iacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica. 2007;92(4):437–439. doi:10.3324/haematol.11248
   PubMed Web of Science ®Google Scholar
• Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109–1118. doi:10.1038/nsmb.1486
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62(15):4236–4243.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. Pharmacol Res. 2021;169:105660. doi:10.1016/j.phrs.2021.105660
   PubMed Web of Science ®Google Scholar
• Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10–20. doi:10.1016/j.leukres.2013.09.011
   PubMed Web of Science ®Google Scholar
• Soverini S, Rosti G, Iacobucci I, Baccarani M, Martinelli G. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC(5)(0)? Oncologist. 2011;16(6):868–876. doi:10.1634/theoncologist.2010-0388
   PubMed Web of Science ®Google Scholar
• Lyczek A, Berger BT, Rangwala AM, et al. Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Proc Natl Acad Sci U S A. 2021;118:46. doi:10.1073/pnas.2111451118
   Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070–1079. doi:10.1182/blood.V96.3.1070
   PubMed Web of Science ®Google Scholar
• Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95(11):3498–3505. doi:10.1182/blood.V95.11.3498
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet. 2002;139(1):30–33. doi:10.1016/S0165-4608(02)00615-5
   PubMedGoogle Scholar
• Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190–2196. doi:10.1038/sj.leu.2402741
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912–8919. doi:10.1158/0008-5472.CAN-05-0076
   PubMed Web of Science ®Google Scholar
• Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008;68(23):9809–9816. doi:10.1158/0008-5472.CAN-08-1008
   PubMed Web of Science ®Google Scholar
• Tang C, Schafranek L, Watkins DB, et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma. 2011;52(11):2139–2147. doi:10.3109/10428194.2011.591013
   PubMed Web of Science ®Google Scholar
• Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18(1):24–30. doi:10.1002/ijc.2910180105
   PubMed Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76–94. doi:10.1159/000046636
   PubMed Web of Science ®Google Scholar
• Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760–6768. doi:10.1182/blood-2011-08-373902
   PubMed Web of Science ®Google Scholar
• Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengio R, Larripa I. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Eur J Haematol. 2009;82(4):292–300. doi:10.1111/j.1600-0609.2008.01199.x
   PubMed Web of Science ®Google Scholar
• Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006;103(40):14907–14912. doi:10.1073/pnas.0606176103
   PubMed Web of Science ®Google Scholar
• Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001;20(43):6188–6195. doi:10.1038/sj.onc.1204834
   PubMed Web of Science ®Google Scholar
• Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21(47):7137–7146. doi:10.1038/sj.onc.1205942
   PubMed Web of Science ®Google Scholar
• Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468–6472. doi:10.1158/0008-5472.CAN-06-0025
   PubMed Web of Science ®Google Scholar
• Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer. 2010;1(4):346–359. doi:10.1177/1947601910372232
   PubMedGoogle Scholar
• Samanta A, Perazzona B, Chakraborty S, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25(3):463–472. doi:10.1038/leu.2010.287
   PubMed Web of Science ®Google Scholar
• Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005;19(10):1774–1782. doi:10.1038/sj.leu.2403898
   PubMed Web of Science ®Google Scholar
• Wagle M, Eiring AM, Wongchenko M, et al. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. 2016;30(7):1493–1501. doi:10.1038/leu.2016.51
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. BCR-ABL Independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690–698. doi:10.1182/blood.V101.2.690
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008;111(7):3821–3829. doi:10.1182/blood-2007-08-109330
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008;100(13):926–939. doi:10.1093/jnci/djn188
   PubMedGoogle Scholar
• Mancini M, Castagnetti F, Soverini S, et al. FOXM1 Transcription Factor: a New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. J Cell Biochem. 2017;118(11):3968–3975. doi:10.1002/jcb.26052
   PubMed Web of Science ®Google Scholar
• Mancini M, De Santis S, Monaldi C, et al. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. J Exp Clin Cancer Res. 2019;38(1):216. doi:10.1186/s13046-019-1197-9
   PubMed Web of Science ®Google Scholar
• Mancini M, De Santis S, Monaldi C, et al. Ponatinib treatment in chronic myeloid leukemia cell lines targets Aurora kinase A/FOXM1 axis. Hematol Oncol. 2020;38(2):201–203. doi:10.1002/hon.2703
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368–2373. doi:10.1182/blood.V101.6.2368
   PubMed Web of Science ®Google Scholar
• Eadie LN, Dang P, Saunders VA, et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2017;31(1):75–82. doi:10.1038/leu.2016.179
   PubMed Web of Science ®Google Scholar
• Reis FR, Vasconcelos FC, Pereira DL, Moellman-Coelho A, Silva KL, Maia RC. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep. 2011;26(2):471–478. doi:10.3892/or.2011.1296
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 2006;108(2):678–684. doi:10.1182/blood-2005-10-4020
   PubMed Web of Science ®Google Scholar
• Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 2008;22(2):445–447. doi:10.1038/sj.leu.2404897
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia. 2007;21(6):1267–1275. doi:10.1038/sj.leu.2404638
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT- 1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697–704. doi:10.1182/blood-2005-11-4687
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT- 1 activity: higher doses of imatinib may overcome the negative impact of low OCT- 1 activity. Blood. 2007;110(12):4064–4072. doi:10.1182/blood-2007-06-093617
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia. 2010;24(11):1962–1965. doi:10.1038/leu.2010.188
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J, et al. Functional activity of the OCT- 1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28(16):2761–2767. doi:10.1200/JCO.2009.26.5819
   PubMed Web of Science ®Google Scholar
• White DL, Radich J, Soverini S, et al. Chronic phase chronic myeloid leukemia patients with low OCT- 1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 2012;97(6):907–914. doi:10.3324/haematol.2011.056457
   PubMed Web of Science ®Google Scholar
• Eadie LN, Hughes TP, White DL. Patients with low OCT- 1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia. 2018;32(10):2288–2291. doi:10.1038/s41375-018-0101-5
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396–409. doi:10.1172/JCI35721
   PubMed Web of Science ®Google Scholar
• Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501–1510. doi:10.1182/blood-2010-12-326843
   PubMed Web of Science ®Google Scholar
• Soverini S, De Santis S, Monaldi C, Bruno S, Mancini M. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: is It Worth the Effort? Int J Mol Sci. 2021;22:13. doi:10.3390/ijms22137093
   Web of Science ®Google Scholar
• Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48. doi:10.1016/j.phrs.2015.10.021
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640–2653. doi:10.1182/blood-2004-08-3097
   PubMed Web of Science ®Google Scholar
• Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84. doi:10.1186/s13045-018-0624-2
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–141. doi:10.1016/j.ccr.2005.01.007
   PubMed Web of Science ®Google Scholar
• Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11(13):4941–4947. doi:10.1158/1078-0432.CCR-04-2601
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. doi:10.1126/science.1099480
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314–11322. doi:10.1158/0008-5472.CAN-06-1199
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Mancini M, Martinelli G. Best Practices in Chronic Myeloid Leukemia Monitoring and Management. Oncologist. 2016;21(5):626–633. doi:10.1634/theoncologist.2015-0337
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. doi:10.1016/j.ccr.2009.09.028
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–1215. doi:10.1182/blood-2010-12-326405
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489–498. doi:10.1182/blood-2012-05-431379
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562–2569. doi:10.1172/JCI30890
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428–442. doi:10.1016/j.ccr.2014.07.006
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Pricl S, Posocco P, et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014;111(9):3550–3555. doi:10.1073/pnas.1321173111
   PubMed Web of Science ®Google Scholar
• Byrgazov K, Lucini CB, Valent P, Hantschel O, Lion T. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica. 2018;103(1):e10–e12. doi:10.3324/haematol.2017.176347
   PubMed Web of Science ®Google Scholar
• Soverini S, Martelli M, Bavaro L, et al. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. Leukemia. 2021;35(7):2102–2107. doi:10.1038/s41375-020-01098-w
   PubMed Web of Science ®Google Scholar
• Garuti L, Roberti M, Bottegoni G. Non-ATP competitive protein kinase inhibitors. Curr Med Chem. 2010;17(25):2804–2821. doi:10.2174/092986710791859333
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem. 2018;61(18):8120–8135. doi:10.1021/acs.jmedchem.8b01040
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019;36(4):431–443 e5. doi:10.1016/j.ccell.2019.08.004
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733–737. doi:10.1038/nature21702
   PubMed Web of Science ®Google Scholar
• Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463(7280):501–506. doi:10.1038/nature08675
   PubMed Web of Science ®Google Scholar
• Packer LM, Rana S, Hayward R, et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 2011;20(6):715–727. doi:10.1016/j.ccr.2011.11.004
   PubMed Web of Science ®Google Scholar
• Eiring AM, Page BDG, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2017;31(5):1253–1254. doi:10.1038/leu.2017.14
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127(6):2392–2406. doi:10.1172/JCI90825
   PubMed Web of Science ®Google Scholar
• Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39. doi:10.1186/s13045-019-0729-2
   PubMed Web of Science ®Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415. doi:10.6004/jnccn.2020.0047
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, Iacobucci I, Baccarani M. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. Pharmacogenomics. 2012;13(11):1271–1284. doi:10.2217/pgs.12.103
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634–1648. doi:10.1182/blood-2013-03-487728
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Castagnetti F, et al. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer. 2016;16:572. doi:10.1186/s12885-016-2635-0
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Polakova KM, et al. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016;7(16):21982–21990. doi:10.18632/oncotarget.8010
   PubMedGoogle Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia. 2016;30(7):1615–1619. doi:10.1038/leu.2016.17
   PubMed Web of Science ®Google Scholar
• Baer C, Kern W, Koch S, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica. 2016;101(7):830–838. doi:10.3324/haematol.2016.145888
   PubMed Web of Science ®Google Scholar
• Machova Polakova K, Kulvait V, Benesova A, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887–899. doi:10.1007/s00432-014-1845-6
   PubMed Web of Science ®Google Scholar